Description
Anti-BCMA CAR Jurkat/NFAT (Luciferase) Reporter Cell Line | 79694 | Gentaur US, UK & Europe Disrtribition
Category: CAR-T/Cell Line
Application: • Predict the MOA of the CAR design • Measurements of antibody (scFV-CAR) specificity • Screen and validate BCMA-expressing caner target cells
Background: The development of CAR-T cells is a complex process that requires I) screening and sequencing of mAbs that are specific to the cancer antigens; II) synthesis of scFv cDNA and clone into Chimeric Antigen Receptor (CAR) cassette in Lentivector (e.g. anti-BCMA scFv in 3rd generation CAR cassette in lentivector); III) packaging and production of high titer lentivirus CAR encoding lentivirus; IV) isolation, activation and expansion of patient-derived T cells that exhibit a specific cellular phenotype (e.g. CD4+ or CD8+ or a mix); V) and transduction of activated T cells with CAR-encoding lentivirus; VI) Validation of engineered CAR-T cells through FACS and functional analysis. BPS has developed an anti-BCMA CAR Jurkat/NFAT-luciferase stable reporter cell line, it is one of a series of reporter bioassays using CAR-T Lentivirus and Jurkat/NFAT-luciferase reporter cell lines. The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a great system to predict the mechanism of action (MOA) and therapeutic potential of the anti-BCMA CAR lentivirus before using it with patient-derived primary T cells. It is a single cell clonal stable cell line developed by transducing the Jurkat/NFAT-Luciferase reporter cells with the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701).
Description: The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (BPS Bioscience #79467) and BCMA/CHO target cells (BPS Bioscience #79500).
Product Type: Cell Line
Shippement Condition: -80°C
